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Arterial hypertension (AH) is one of
the most common pathological condi-
tions affecting the general population
which contributes to pathogenesis of
various diseases and worsens the treat-
ment outcome (James et al., 2014). It
increases the perioperative morbidity and
mortality, frequently result in cancela-
tion of surgical procedures and increases
treatment-associated costs (Handler,
2006). Perioperative hypertension may
occur in patients with pre-existing arte-
rial hypertension or manifest as a de novo
phenomenon (Vuylsteke et al., 2000; Varon
and Marik, 2008).
Induction of general anesthesia is
related with significant stress and sympa-
thetic over-activation. The systolic blood
pressure (SBP) in normotensive patients
may increase by up to 20–30mmHg, while
hypertensive patients may have an exag-
gerated reaction—SBP in these patients
may increase up to 90mmHg (Ahuja
and Charap, 2010). On the other hand,
anesthesia-induced sympathetic suppres-
sion with diminished baroreceptor reflex
takes place during the maintenance phase
which frequently causes sustained arte-
rial hypotension. Postoperatively, these
patients present with labile BP, frequent
and rebound hypertension, and have an
increased risk of postoperative compli-
cations (Goldman and Caldera, 1979;
Wolfsthal, 1993).
Joint National Committee on
Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC-7
and JNC-8) classifications and guidelines
are currently applicable to perioperative
patients as well (James et al., 2014;
Chobanian et al., 2003).
According to JNC-7 guidelines for eval-
uation and treatment of hypertensive
emergencies, an immediate intervention is
required in cases of hypertensive emer-
gencies to reduce the SBP by 10–15%
(no more than 25%) within the first
hour. Reduction of the absolute BP to
160/110mmHg should be done gradu-
ally over the following 2–6 h (Aggarwal
and Khan, 2006; Flanigan and Vitberg,
2006; Pollack and Varon, 2008; Varon,
2008; De Gaudio et al., 2009; Hays and
Wilkerson, 2010; Kuppasani and Reddi,
2010; Smithburger et al., 2010; Polly
et al., 2011). Only in patients with
aortic dissection, the SBP should be
reduced to less than 120mmHg within
20min. In hypertensive emergencies asso-
ciated with ischemic stroke, BP must be
decreased to less than 180/110 before
thrombolytic therapy may be adminis-
tered (Pollack and Varon, 2008; Varon,
2008; De Gaudio et al., 2009; Hays and
Wilkerson, 2010; Polly et al., 2011). Abrupt
BP reduction should be avoided as it
can result in critical blood flow reduc-
tion and ischemic end organ damage
(Varon, 2008; De Gaudio et al., 2009;
Smithburger et al., 2010; Polly et al.,
2011).
Since overshooting a target BP in
hypertensive patients is associated with
worse outcome, many treatment protocols
require invasive arterial blood pressure
monitoring during anesthesia in high risk
cases (Pollack and Varon, 2008; Rhoney
and Peacock, 2009).
Hypertensive emergencies should be
treated aggressively, using quick-onset
intravenous medications, whereas hyper-
tensive urgencies do not always require
such aggressive treatment. Longer acting
oral medications (labetalol, clonidine, etc.)
may be more appropriate in situations
of hypertensive urgency. However, cau-
tion should be exercised when using anti-
hypertensive agents in the acute setting. An
overly aggressive treatment approach may
lead to organ hypoperfusion (Rodriguez
et al., 2010). Once the immediate threat of
organ damage is diminished, BP should be
gradually brought to baseline level within
a period of 24–48 h (Peacock et al., 2009).
Characteristics of an ideal intravenous
hypertensive agent are rapid onset and
offset of action, low risk of hypoten-
sion, minimal drug interaction with other
medications, lack of adverse reactions,
wide therapeutic window, ease of titration,
preservation of renal and hepatic func-
tions, selectivity, low cost, possibility of
easy transition to oral therapy, predictable
response, and lack of effects on intracra-
nial pressure (Levy, 1999; Oparil et al.,
1999). Multiple intravenous medications
are currently used to control the BP in the
perioperative period, and all these medi-
cations have specific advantages and limi-
tations (Kurnutala et al., 2013).
Selection of an optimal antihyperten-
sive therapy for the perioperative period
depends on the patient’s individual char-
acteristics and locally adopted guidelines
(Pollack and Varon, 2008; Belsha, 2013).
Clevidipine butyrate is a Ca2+-channel
antagonist that acts on the L-type Ca2+
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channels regulating the influx of Ca2+
ions into the arteriolar smooth muscle
cells during depolarization. It has recently
raised significant interest among anesthe-
siologists and surgeons as a valuable agent
to control AH during surgery because of
its fast and selective action and ease of
BP control. Clevidipine selectively dilates
the arterioles and reduces peripheral
resistance, thus increasing stroke volume
and cardiac output. Like nicardipine and
nifedipine, it belongs to the subclass of
dihydropyridines—a group of drugs con-
sidered a first-line treatment for hyper-
tensive emergencies because of strong
vasodilating effects and low propensity to
cause cardiac conduction and contractil-
ity abnormalities (Eisenberg et al., 2004;
Nordlander et al., 2004; FDA/CDER, 2008;
Bergese and Puente, 2010; The Medicines
Company, 2011; Tulman et al., 2012).
Clevidipine butyrate was approved by
FDA in 2008. Interestingly, it was the
only intravenous antihypertensive drug
approved during the past 10 years.
The pharmacologic characteristics of
clevidipine are beneficial for its use dur-
ing the perioperative period. The drug
formulation represents a racemic mix-
ture of equipotent S- and R-enantiomers
(Noviawaty et al., 2008; Sorbera and
Castanera, 2004). The preparation is a
sterile lipid emulsion with pH of 6.0–8.0
ready for intravenous use (Sorbera and
Castanera, 2004; Noviawaty et al., 2008).
As with other lipid solutions (intralipid,
propofol), strict asepsis must be main-
tained during administration to pre-
vent bacterial contamination and growth.
Clevidipine must be discarded 12 h after
puncturing the stopper. The drug is
metabolized by plasma and tissue esterases
to inactive metabolites with a mean blood
clearance rate of 0.121 lit. min−1 kg−1
(Ericsson et al., 1999a). Up to 99.7% of
circulating clevidipine is bound to plasma
proteins. The elimination rate does not
depend on hepatic and renal clearance and
it can be safely administered in patients
with hepatic and renal pathology (Ericsson
et al., 1999b).
During anesthesia, clevidipine is
administered as a slow rate intravenous
infusion. As with other lipid solutions, the
drug is contraindicated in cases of allergy
to soy and egg products and in patients
with defective lipid metabolism. The drop
in BP equaling 4–5% of the initial value
takes place within 2–4min after starting
the infusion.
Clevidipine has many features of an
ideal antihypertensive drug that can be
used in emergency situations. These fea-
tures include fast onset and offset of clin-
ical effects, ease of titration, small volume
of distribution and fast elimination inde-
pendent on hepatic and renal clearance
(Ericsson et al., 1999a,b; Prlesi and Cheng-
Lai, 2009).
Clinical trials showed that the racemic
formulation of clevidipine is superior to
L or R enantiomers in controlling AH
(Schwieler et al., 1999; Ericsson et al.,
2000).
In patients undergone elective car-
diac interventions, clevidipine was effec-
tive in controlling the mean BP and
systemic vascular resistance in a dose-
dependent manner. The drug did not
cause any cardiovascular instability or
metabolic changes (Kieler-Jensen et al.,
2000; Ericsson et al., 2001; Bailey et al.,
2002).
Two randomized double blind, placebo
controlled trials performed in cardiosur-
gical patients (ESCAPE1 and ESCAPE2)
showed that in 92.5–91.8% of patients
the desired SBP values could be achieved
within 4–7min after starting the drug
infusion (Levy et al., 2007; Singla et al.,
2008). Aronson et al., compared clevidip-
ine with other commonly used antihyper-
tensive drugs in cardiac surgery (Aronson
et al., 2008). In this study, the clevidip-
ine group achieved superior BP control
compared with other drugs and had a sig-
nificantly lower 30-day mortality rate than
sodium nitroprusside. Pollack et al. (2009)
evaluated the efficacy and safety of pro-
longed infusion of clevidipine (up to 96 h)
(Pollack et al., 2009). In 88.9% of patients,
the target SBP could be achieved within
half an hour after starting the infusion. In
1.6% of cases the SBP dropped below the
target range.
The ACCELERATE trial evaluated the
efficacy of clevidipine in management of
severe AH associated with intracerebral
hemorrhage (Graffagnino et al., 2013).
Again, the clevidipine infusion helped to
rapidly reduce the BP to the desired level
(<160mm Hg) within a few minutes.
Clevidipine can be effectively used
during elective neurosurgical procedures,
including neurovascular interventions, to
control the BP during intraoperatively and
in the postoperative period (Bekker et al.,
2010; Varelas et al., 2014).
Another area of surgery, where clev-
idipine can be used with success is surgical
resection of pheochromocytoma (Kline,
2010; Bettesworth et al., 2013).
More research is required to clarify
the safety of clevidipine in pregnant and
breastfeeding patients. In these patients,
the drug should be used with caution and
only when the benefits of such therapy
will clearly outweigh the potential risks
(The Medicines Company, 2011). Another
area of research is pediatric population,
even though several case reports suggest
that clevidipine may be considered a safe
option in pediatric patients (Tobias et al.,
2009, 2011, 2013; Towe and Tobias, 2010;
Tobias and Hoernschemeyer, 2011).
As a conclusion, Clevidipine butyrate
is an easily controlled and effective drug
that can be safely used in various surgi-
cal patients to control the BP. The drug has
minimal side effects and can be titrated to
reach the desired clinical effect. It can be
safely used in patients with hepato-renal
pathology. Further research is required
to clarify clevidipine’s efficacy, safety and
limitations in pregnant and breastfeeding
women and pediatric surgical patients.
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